NSTEMI Type 1 and Type 2 Differentiation and Management

Pathophysiology

Type 1 NSTEMI is caused by acute coronary atherothrombosis from plaque rupture or erosion, while Type 2 NSTEMI results from a supply-demand mismatch unrelated to acute coronary atherothrombosis, according to the American Heart Association 1, 2
Type 1 NSTEMI is caused by atherosclerotic plaque disruption with subsequent partial or complete vessel thrombosis, as stated by the American College of Cardiology 1
Type 2 NSTEMI is caused by myocardial oxygen supply-demand imbalance without acute coronary atherothrombosis, as noted by the American Heart Association 1, 2

Both Type 1 and Type 2 NSTEMI present with elevated cardiac troponin with characteristic rise/fall pattern, according to the American College of Cardiology 2, 3
Both typically present without ST-segment elevation on ECG, as stated by the American Heart Association 1
Type 2 NSTEMI patients have identifiable precipitating factors and multiple comorbidities, as noted by the American College of Cardiology 2

Aggressive antiplatelet therapy is indicated for Type 1 NSTEMI, with dual antiplatelet therapy with aspirin plus P2Y12 inhibitor, as recommended by the American College of Cardiology 1
Anticoagulation therapy with heparin or low molecular weight heparin is also indicated for Type 1 NSTEMI, according to the American College of Cardiology 1
Early invasive strategy with coronary angiography and revascularization is recommended for high/intermediate risk Type 1 NSTEMI patients, as stated by the American College of Cardiology 1
For Type 2 NSTEMI, primary focus is on treating the underlying precipitating cause of the supply-demand mismatch, as noted by the American College of Cardiology 2
Antiplatelet therapy is not universally indicated for Type 2 NSTEMI and may be contraindicated, according to the American College of Cardiology 2, 4

Prognosis for Type 1 NSTEMI is primarily determined by extent of coronary disease and myocardial damage, and benefits significantly from revascularization strategies, as stated by the American College of Cardiology 1
Prognosis for Type 2 NSTEMI depends on severity of the underlying precipitating condition rather than coronary disease, according to the American College of Cardiology 2
Type 2 NSTEMI has higher in-hospital mortality and higher 30-day and 1-year mortality compared to Type 1, as noted by the American College of Cardiology 2